ELDN Stock Analysis: Eledon Pharmaceuticals | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 304m USD | 12M Return: 26.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.68M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Eledon Pharmaceuticals (ELDN) is a U.S.-based clinical-stage biotechnology company developing therapies that target the CD40 Ligand (CD40L) immune pathway. Its lead candidate, tegoprubart, is an anti-CD40L antibody being studied to prevent organ transplant rejection and to treat amyotrophic lateral sclerosis (ALS), with additional programs in kidney and xenotransplantation. The company has collaboration agreements with eGenesis and NewcelX, the latter focused on a Type 1 Diabetes therapy.
As a clinical-stage biotech, Eledon is pre-commercial and primarily relies on research partnerships and capital markets to fund its development pipeline. The company was previously named Novus Therapeutics before rebranding in January 2021, and is headquartered in Irvine, California.
- Tegoprubart Phase 2 data readout in kidney transplant rejection prevention
- FDA fast track or orphan drug designation elevates tegoprubart profile
- Cash runway extension needed as clinical-stage biotech faces dilution risk
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.47 > 0.02 and ΔFCF/TA -35.50 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.47 > 3% & CFO -68.9m > Net Income -78.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.44 > 1.5 & < 3 |
| Outstanding Shares: last quarter (112.4m) vs 12m ago 45.77% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.59%; Δ -0.59% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.68 (Total Current Assets 113.6m - Total Current Liabilities 13.5m) / Total Assets 146.7m |
| B: -3.00 (Retained Earnings -440.2m / Total Assets 146.7m) |
| C: -0.56 (EBIT TTM -86.5m / Avg Total Assets 154.0m) |
| D: 2.17 (Book Value of Equity 100.5m / Total Liabilities 46.2m) |
| Altman-Z'' = -6.80 = D |
As of July 08, 2026, the stock is trading at USD 3.93 with a total of 1,750,464 shares traded. Over the past week, the price has changed by +1.29%, over one month by +9.78%, over three months by +28.85% and over the past year by +26.37%.
Current recommended Stop Loss: 3.40 (which is 13.5% or 1.9 ATR below the current price).
Eledon Pharmaceuticals has received a consensus analysts rating of 4.83. Therefore, it is recommended to buy ELDN.
- StrongBuy: 5
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 9 | 129% |
P/E Forward = 5.3908
P/B = 6.7939
Revenue TTM = 0.0 USD
EBIT TTM = -86.5m USD
EBITDA TTM = -86.2m USD
Long Term Debt = 186k USD (estimated: total debt 555k - short term 369k)
Short Term Debt = 369k USD (from shortTermDebt, last quarter)
Debt = 555k USD (from shortLongTermDebtTotal, last quarter) (leases 555k already included)
Net Debt = -100.5m USD (calculated: Debt 555k - CCE 101.0m)
Enterprise Value = 203.7m USD (304.1m + Debt 555k - CCE 101.0m)
Interest Coverage Ratio = unknown (Ebit TTM -86.5m / Interest Expense TTM 0.0)
EV/FCF = -2.98x (Enterprise Value 203.7m / FCF TTM -68.3m)
FCF Yield = -33.52% (FCF TTM -68.3m / Enterprise Value 203.7m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 1.39 (Enterprise Value 203.7m / Total Assets 146.7m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 555k)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -68.3m (EBIT -86.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.67 (Total Current Assets 113.6m / Total Current Liabilities 20.0m)
Debt / Equity = 0.01 (Debt 555k / totalStockholderEquity, last quarter 100.5m)
Debt / EBITDA = 1.17 (negative EBITDA) (Net Debt -100.5m / EBITDA -86.2m)
Debt / FCF = 1.47 (negative FCF - burning cash) (Net Debt -100.5m / FCF TTM -68.3m)
Total Stockholder Equity = 80.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -50.75% (Net Income -78.1m / Total Assets 146.7m)
RoE = -96.80% (Net Income TTM -78.1m / Total Stockholder Equity 80.7m)
RoCE = -106.9% (out of range, set to none) (EBIT -86.5m / Capital Employed (Equity 80.7m + L.T.Debt 186k))
RoIC = -51.14% (negative operating profit) (NOPAT -68.3m / Invested Capital 133.6m)
WACC = 9.60% (E(304.1m)/V(304.7m) * Re(9.62%) + D(555k)/V(304.7m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.62% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 85.40 | Cagr: 97.86%
[DCF] Fair Price = unknown (Cash Flow -68.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.19 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.15 | Chg30d=+0.00% | Revisions=+40% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-0.18 | Chg30d=+0.00% | Revisions=+40% | Analysts=4
EPS current Year (2026-12-31): EPS=-0.87 | Chg30d=+0.00% | Revisions=+40% | GrowthEPS=-67.8% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.72 | Chg30d=+0.00% | Revisions=+40% | GrowthEPS=+17.1% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +73% (up=8, down=0)